Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

ALT5 Sigma Corporation ALTS

Financial Services
ALT5 Sigma Corporation, together with its subsidiaries, provides blockchain-powered technologies worldwide. It operates through Fintech and Biotechnology segments. The company engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. Its products include ALT 5 Prime, an electronic over-the-counter trading platform for the buying and selling of digital assets; and ALT 5 Pay, a crypto-currency payment gateway that enables merchants to accept and make crypto currency payments or integrate the payment platform into their application. The company is also involved identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies for the treatment of pain and addiction. In addition, it develops JAN 101, an oral and sustained-release pharmaceutical composition of sodium nitrite that has completed Phase 2a clinical trial to treat peripheral arterial disease and pain; and JAN123, a formul...


NDAQ:ALTS - Post by User

ALT5 Sigma Corporation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(187)
•••
  • coolfooldumbguyX
Post by coolfooldumbguyon Jan 14, 2026 9:12am
9 Views
Post# 36858327

Buy buddy buy because it's taking off this morning.

Buy buddy buy because it's taking off this morning.Otherwise it will be FOMO time for you fellas todayanyway,so good luck to all of you guys
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities